AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 FEB 4 - (NewsRx.com & NewsRx.net) -- Intravenous inoculation of replication-deficient recombinant vaccinia virus DIs expressing simian immunodeficiency virus (SIV) gag controls highly pathogenic SHIV in monkeys.
"To be effective, a vaccine against human immunodeficiency virus type 1 (HIV-1) must induce virus-specific T-cell responses and it must be safe for use in humans. To address these issues, we developed a recombinant vaccinia virus DIs vaccine (rDIsSIVGag), which is nonreplicative in mammalian cells and expresses the full-length gag gene of simian immunodeficiency virus (SIV). Intravenous inoculation of 10[superscript]6 PFU of rDIsSIVGag in cynomologus macaques induced significant levels of gamma interferon (IFN-gamma) spot-forming cells (SFC) specific for SIV Gag," scientists in Japan report.
"Antigen-specific lymphocyte proliferative responses were also induced and were temporally associated with the peak of IFN-gamma SFC activity in each macaque," stated Yasuyuki Izumi and collaborators at the National Institute of Infectious Diseases in Tokyo and Technology Corporation in Saitama. "In contrast, macaques immunized with a vector control (rDIsLacZ) showed no significant induction of antigen-specific immune responses."
"After challenge with a highly pathogenic simian-human immunodeficiency virus (SHIV), CD4+ T lymphocytes were maintained in the peripheral blood and ...
Source: HighBeam Research, Vaccinia virus DIs expressing SIV gag controls SHIV in monkeys.